한국임상암학회 전이성 전립선암 치료 지침

키워드

참고문헌 (93)

1. 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2015", Cancer Research and Treatment, 47(2), pp.142~148 (2015), 대한암학회[DOI]
2. Loblaw DA, "Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline", J Clin Oncol, 25, pp.1596~1605 (2007)
3. Petrylak DP, "Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer", N Engl J Med, 351, pp.1513~1520 (2004)
4. Tannock IF, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer", N Engl J Med, 351, pp.1502~1512 (2004)
5. de Bono JS, "Abiraterone and increased survival in metastatic prostate cancer", N Engl J Med, 364, pp.1995~2005 (2011)
6. Ryan CJ, "Abiraterone in metastatic prostate cancer without previous chemotherapy", N Engl J Med, 368, pp.138~148 (2013)
7. Beer TM, "Enzalutamide in metastatic prostate cancer before chemotherapy", N Engl J Med, 371, pp.424~433 (2014)
8. Scher HI, "Increased survival with enzalutamide in prostate cancer after chemotherapy", N Engl J Med, 367, pp.1187~1197 (2012)
9. de Bono JS, "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:a randomised open-label trial", Lancet, 376, pp.1147~1154 (2010)
10. Parker C, "Alpha emitter radium-223 and survival in metastatic prostate cancer", N Engl J Med, 369, pp.213~223 (2013)
11. Chang SH, "Clinical Guidelines on Prostate Carcinoma", pp.76~97 (2009), PentAid
12. Kim TH, "Clinical Guidelines on Prostate Carcinoma", pp.98~113 (2009), PentAid
13. Kang TW, "Treatment guidelines of prostate cancer" (2012), The Korean Prostate Society
14. "NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer" (2016)[URL]
15. Cookson MS, "Castration-resistant prostate cancer:AUA guideline amendment", J Urol, 193, pp.491~499 (2015)
16. Loblaw DA, "Systemic therapy in men with metastatic castration-resistant prostate cancer:a systematic review", Clin Oncol, 25, pp.406~430 (2013)
17. Basch E, "Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline", J Clin Oncol, 32, pp.3436~3448 (2014)
18. Heidenreich A, "EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer", Eur Urol, 65, pp.467~479 (2014)
19. Horwich A, "Prostate cancer: ESMO Consensus Conference Guidelines 2012", Ann Oncol, 24, pp.1141~1162 (2013)
20. Scher HI, "Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group", J Clin Oncol, 26, pp.1148~1159 (2008)
21. Scher HI, "Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3", J Clin Oncol, 34, pp.1402~1418 (2016)
22. Droz JP, "Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology", Lancet Oncol, 15, pp.e404~e414 (2014)
23. "Level of Evidence" (2014)[URL]
24. Guyatt GH, "GRADE: an emerging consensus on rating quality of evidence and strength of recommendations", BMJ, 336, pp.924~926 (2008)
25. Seidenfeld J, "Single-therapy androgen suppression in men with advanced prostate cancer:a systematic review and meta-analysis", Ann Intern Med, 132, pp.566~577 (2000)
26. Klotz L, "The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer", BJU Int, 102, pp.1531~1538 (2008)
27. Iversen P, "Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators", Eur Urol, 26(Suppl 1), pp.5~9 (1994)
28. Tyrrell CJ, "A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer", Eur Urol, 33, pp.447~456 (1998)
29. Iversen P, "Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup", J Urol, 164, pp.1579~1582 (2000)
30. "Maximum androgen blockade in advanced prostate cancer:an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group", Lancet, 355, pp.1491~1498 (2000)
31. Schellhammer PF, "Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma:final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group", Urology, 50, pp.330~336 (1997)
32. Akaza H, "Combined androgen blockade with bicalutamide for advanced prostate cancer:long-term follow-up of a phase 3, double-blind, randomized study for survival", Cancer, 115, pp.3437~3445 (2009)
33. Byar DP, "Proceedings: the veterans administration cooperative urological research group's studies of cancer of the prostate", Cancer, 32, pp.1126~1130 (1973)
34. Kirk D, "Timing and choice of androgen ablation", Prostate Cancer Prostatic Dis, 7, pp.217~222 (2004)
35. Studer UE, "Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08", 88, 2004, pp.22, 4109~4118
36. Studer UE, "Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891", J Clin Oncol, 24, pp.1868~1876 (2006)
37. "Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group", Br J Urol, 79, pp.235~246 (1997)
38. Studer UE, "Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2M0 prostate cancer not suitable for local curative treatment (EORTC 30891)", Eur Urol, 53, pp.941~949 (2008)
39. Calais da Silva FE, "Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group", Eur Urol, 55, pp.1269~1277 (2009)
40. Crook JM, "Intermittent androgen suppression for rising PSA level after radiotherapy", N Engl J Med, 367, pp.895~903 (2012)
41. de Leval J, "Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial", Clin Prostate Cancer, 1, pp.163~171 (2002)
42. Hussain M, "Intermittent versus continuous androgen deprivation in prostate cancer", N Engl J Med, 368, pp.1314~1325 (2013)
43. Langenhuijsen JF, "Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer", Urol Oncol, 31, pp.549~556 (2013)
44. Mottet N, "Intermittent hormonal therapy in the treatment of metastatic prostate cancer:a randomized trial", BJU Int, 110, pp.1262~1269 (2012)
45. Salonen AJ, "The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer", J Urol, 187, pp.2074~2081 (2012)
46. Niraula S, "Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials", J Clin Oncol, 31, pp.2029~2036 (2013)
47. Gravis G, "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial", Lancet Oncol, 14, pp.149~158 (2013)
48. Glass TR, "Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning", J Urol, 169, pp.164~169 (2003)
49. Sweeney CJ, "Chemohormonal therapy in metastatic hormone-sensitive prostate cancer", N Engl J Med, 373, pp.737~746 (2015)
50. James ND, "Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial", Lancet, 387, pp.1163~1177 (2016)
51. Vale CL, "Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data", Lancet Oncol, 17, pp.243~256 (2016)
52. Oefelein MG, "Reassessment of the definition of castrate levels of testosterone:implications for clinical decision making", Urology, 56, pp.1021~1024 (2000)
53. Small EJ, "Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)", J Clin Oncol, 22, pp.1025~1033 (2004)
54. Shamash J, "A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer", Br J Cancer, 98, pp.22~24 (2008)
55. Lee JL, "Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy", Am J Clin Oncol, 34, pp.140~144 (2011)
56. Knudsen KE, "Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer", Clin Cancer Res, 15, pp.4792~4798 (2009)
57. Montgomery RB, "Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth", Cancer Res, 68, pp.4447~4454 (2008)
58. Kantoff PW, "Sipuleucel-T immunotherapy for castration-resistant prostate cancer", N Engl J Med, 363, pp.411~422 (2010)
59. Wang HT, "Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis", J Clin Oncol, 32, pp.3383~3390 (2014)
60. Brawn PN, "The dedifferentiation of metastatic prostate carcinoma", Br J Cancer, 59, pp.85~88 (1989)
61. Ismail AH, "Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate", Prostate, 51, pp.117~125 (2002)
62. Hirano D, "Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy", Eur Urol, 45, pp.586~592 (2004)
63. Smith TJ, "American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care", J Clin Oncol, 30, pp.880~887 (2012)
64. Houterman S, "Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study", Crit Rev Oncol Hematol, 58, pp.60~67 (2006)
65. Basch E, "Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial", Lancet Oncol, 14, pp.1193~1199 (2013)
66. Ryan CJ, "Final overall survival analysis of COU-AA-301, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (MCRPC) patients without prior chemotherapy", Ann Oncol, 25, pp.iv255~ (2014)
67. Berthold DR, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study", J Clin Oncol, 26, pp.242~245 (2008)
68. Kellokumpu-Lehtinen PL, "2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3trial", Lancet Oncol, 14, pp.117~124 (2013)
69. Caffo O, "Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial", BJU Int, 102, pp.1080~1085 (2008)
70. Eymard JC, "Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer", Ann Oncol, 18, pp.1064~1070 (2007)
71. Hahn NM, "Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis", Clin Cancer Res, 12(20 Pt 1), pp.6094~6099 (2006)
72. Machiels JP, "Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer", J Clin Oncol, 26, pp.5261~5268 (2008)
73. Qi WX, "Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials", J Cancer Res Clin Oncol, 137, pp.1785~1790 (2011)
74. Fizazi K, "Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer:final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study", Lancet Oncol, 13, pp.983~992 (2012)
75. Harland S, "Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy", Eur J Cancer, 49, pp.3648~3657 (2013)
76. Fizazi K, "Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial", Lancet Oncol, 15, pp.1147~1156 (2014)
77. Tannock IF, "Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points", J Clin Oncol, 14, pp.1756~1764 (1996)
78. Kantoff PW, "Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study", J Clin Oncol, 17, pp.2506~2513 (1999)
79. Horwich A, "Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 24(Suppl 6), pp.vi106~vi114 (2013)
80. Saad F, "Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer", J Natl Cancer Inst, 96, pp.879~882 (2004)
81. Saad F, "A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma", J Natl Cancer Inst, 94, pp.1458~1468 (2002)
82. Small EJ, "Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer", J Clin Oncol, 21, pp.4277~4284 (2003)
83. Elomaa I, "Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer", Int Urol Nephrol, 24, pp.159~166 (1992)
84. Kylmälä T, "Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer", Br J Cancer, 76, pp.939~942 (1997)
85. Strang P, "The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer", Anticancer Res, 17, pp.4717~4721 (1997)
86. Ernst DS, "Randomized, double-blind, controlled trial of mitoxantrone", prednisone and clodronate versus mitoxantrone, J Clin Oncol, pp.2003, 21[DOI]
87. Fizazi K, "Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study", Lancet, 377, pp.813~822 (2011)
88. Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
89. Schwartz LH, "RECIST 1.1 -standardisation and disease-specific adaptations: perspectives from the RECIST working group", Eur J Cancer, 62, pp.138~145 (2016)
90. Nelius T, "Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy", Int Urol Nephrol, 40, pp.97~104 (2008)
91. Olbert PJ, "Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel", Anticancer Drugs, 17, pp.993~996 (2006)
92. Ryan CJ, "Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response", Clin Cancer Res, 17, pp.4854~4861 (2011)
93. Smith PH, "Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC urological group", Cancer, 66(5 Suppl), pp.1009~1016 (1990)

관련 논문AI추천